ARW ON RNA
What Baby KJ Taught Us About Patient & Physician Communication
Over the past few weeks, I’ve been sharing my takeaways from the overall event, as well as from a specific panel featuring JHU’s Jeff Coller, CHOP’s Rebecca Ahrens-Nicklas, and Plowshare Therapies’ Kevin Strauss. Together, these three discussed the biggest learnings and takeaways from the miraculous Baby KJ experience that we very much hope to replicate in the future. As you can likely imagine, patient and physician communication played a large role in the discussion at hand.
OUR EXPERT NETWORK
-
RNA Oligonucleotide Synthesis: How Advanced Manufacturing Technologies Are Accelerating Innovation
From a tech perspective, the manufacturing objective is shifting toward integrated process optimization. Automated reaction control, multivariate analytics, and more can connect molecular quality with operational performance.
-
AI Agents Are Only As Good As The RNA Knowledge Behind Them
The RNA field is producing extraordinary volumes of information. Yet, giving an AI system access to more information does not necessarily make the system more scientifically intelligent.
-
Will 2027 See A Meteoric Rise Of Programmable Nanomedicine?
The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.
-
From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2)
Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.
-
Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics
Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.
WEBINARS
MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
RNA HOT TAKES
- Sticks, Carrots, & Carolina Reapers: Fact-Checking The "Death" Of The US mRNA Industry
- mRNA Hot Takes: Ghost Peppers & Global R&D
- mRNA Hot Takes: Habaneros & Headwinds
- The Trough Of Disillusionment: 2026 RNA Reality Checks
- mRNA Hot Takes: Fighting Complacency And "Alternative Facts" In 2026
- mRNA Hot Takes: Building A Solid Foundation For Your RNA Company & Products
VIRTUAL EVENTS
- The mRNA Therapeutics Regulatory Paradigm: A Closer Look
- Evolutions in mRNA Drug Product Analytical Development
- Closing The Adoption Gap For Advanced Single-Use Materials
- Advancements in gRNA Manufacturing & Quality
- Chemoenzymatic Ligation: A New Frontier In siRNA Manufacturing
- Advancements In Targeted LNP Therapy
NEWSLETTER ARCHIVE
- 09.02.26 -- What Baby KJ Taught Us About Sustainable mRNA Development
- 08.26.26 -- The 3 Pillars Of Next-Gen mRNA Expansion
- 08.19.26 -- 5 Critical Regulatory Topics To Watch In The Oligo Sector
- 08.13.26 -- When Innovation Meets Scale
- 08.12.26 -- Can Oligo Regulations Keep Up With Manufacturing Innovation?
- 08.05.26 -- What The Future Holds For Oligo Quality